TY  - JOUR
AU  - Vela-Navarrete, Remigio
AU  - Alcaraz, Antonio
AU  - Rodríguez-Antolín, Alfredo
AU  - Miñana López, Bernardino
AU  - Fernández-Gómez, Jesús M
AU  - Angulo, Javier C
AU  - Castro Díaz, David
AU  - Romero-Otero, Javier
AU  - Brenes, Francisco J
AU  - Carballido, Joaquín
AU  - Molero García, José Mª
AU  - Fernández-Pro Ledesma, Antonio
AU  - Cózar Olmos, José Manuel
AU  - Manasanch Dalmau, José
AU  - Subirana Cachinero, Isaac
AU  - Herdman, Michael
AU  - Ficarra, Vincenzo
PY  - 2018
DO  - 10.1111/bju.14362
UR  - http://hdl.handle.net/10668/12391
T2  - BJU international
AB  - To comprehensively evaluate the efficacy and safety of the hexanic extract of Serenoa repens (HESr, Permixon® ; Pierre Fabre Médicament, Castres, France), at a dose of 320 mg daily, as monotherapy for the treatment of lower urinary tract symptoms...
LA  - en
KW  - Serenoa repens
KW  - LUTS/BPH
KW  - Permixon
KW  - hexanic extract
KW  - meta-analysis
KW  - systematic review
KW  - Androgen Antagonists
KW  - Biomarkers
KW  - Humans
KW  - Inflammation
KW  - Lower Urinary Tract Symptoms
KW  - Male
KW  - Observational Studies as Topic
KW  - Phytotherapy
KW  - Plant Extracts
KW  - Prostatic Hyperplasia
KW  - Randomized Controlled Trials as Topic
KW  - Serenoa
KW  - Treatment Outcome
TI  - Efficacy and safety of a hexanic extract of Serenoa repens (Permixon® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies.
TY  - research article
VL  - 122
ER  -